The industry is right on the cusp of blowing allogeneic cell therapies wide open! Issues with allo cell potency and persistence are slowing becoming a thing of the past: “Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy.” IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
Ryan Murray, PhD’s Post
More Relevant Posts
-
All that you need to know about enabling #mRNA delivery for transient protein expression with minimal toxicity via #LNP to address a range of manufacturing and safety challenges facing CAR-T Cell Therapy. #nanomedicine #cartcelltherapy #celltherapy
By enabling messenger RNA (mRNA) delivery for transient protein expression with minimal toxicity, lipid nanoparticles have the potential to address a range of manufacturing and safety challenges facing the CAR T-cell therapy field. As new studies are published demonstrating their advantages, it may not be long before LNPs start to displace electroporation in the non-viral CAR T delivery field. Read this article to learn more about the role LNPs are playing to advance CAR T cell therapies. #mrna #LNP #cartcelltherapy #tcells
Transient expression of RNA for CAR T-cell therapies: An emerging opportunity for lipid nanoparticles - Pharmaceutical Technology
pharmaceutical-technology.com
To view or add a comment, sign in
-
By enabling messenger RNA (mRNA) delivery for transient protein expression with minimal toxicity, lipid nanoparticles have the potential to address a range of manufacturing and safety challenges facing the CAR T-cell therapy field. As new studies are published demonstrating their advantages, it may not be long before LNPs start to displace electroporation in the non-viral CAR T delivery field. Read this article to learn more about the role LNPs are playing to advance CAR T cell therapies. #mrna #LNP #cartcelltherapy #tcells
Transient expression of RNA for CAR T-cell therapies: An emerging opportunity for lipid nanoparticles - Pharmaceutical Technology
pharmaceutical-technology.com
To view or add a comment, sign in
-
Brainstorm Cell Therapeutics Announces Peer-reviewed Publication of #Biomarker Data from NurOwn's® Phase 3 Clinical Trial in #ALS. NurOwn treatment resulted in a positive impact on important #CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. https://lnkd.in/gv7R7FY3
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
ir.brainstorm-cell.com
To view or add a comment, sign in
-
Leading CAR-T investigators put together commentaries toward the US FDA's concerns on T cell malignancies, including chimeric antigen receptor (CAR)-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR-T cell immunotherapies. The risk of T cell malignancies is applicable to all 6 approved BCMA-directed and CD19-directed genetically modified autologous CAR-T therapies (including Kymriah, Breyanzi, Yescarta, Tecartus, Abecma, Carvykti). Peter Marks, Director of the Center for Biologics Evaluation and Research, U.S. FDA stated on Monday (at ARM Cell & Gene State of the Industry Briefing) that "The overall benefits of (approved) CAR-T products continue to outweigh their potential risks for all approved uses" (Youtube Link: https://lnkd.in/ep4jhnXM). The CAR-T products were approved with the requirement to conduct 15-year long-term follow-up observational safety studies to assess the long-term safety and the risk of secondary or subsequent malignant neoplasms occurring after treatment. Peter now states that patients and participants of clinical trials receiving treatment with these products should be monitored life-long for new malignancies. The FDA hopes to provide the community with further information in early 2024. Dr. Bruce Levine posted a thread yesterday, along with the Nat Med comments, for some insightful discussions: https://lnkd.in/eTZjfP_s Nat Med publication link: https://lnkd.in/eibceMS5
To view or add a comment, sign in
-
-
Cartesian Therapeutics, an mRNA cell therapy biotech, announced its BCMA-directed CAR-T therapy Descartes-08 met the primary endpoint in a Phase 2b study for the nerve communication-destroying disease myasthenia gravis (MG). The biotech switched its primary endpoint from the MG-ADL symptom scale to MGC. Descartes-08 helped 71% of patients achieve 5-point or greater improvement on a 60-point scale of the disease. That compared to 25% of patients who received placebo, with a p-value of 0.018. Cartesian did share results from a per-protocol population that included 31 patients. In that population, the MGC response rates in the Descartes-08 and placebo arms were 69% and 33%, respectively, resulting in a p-value of 0.048
Cartesian claims phase 2b autoimmune CAR-T win after changing endpoint
fiercebiotech.com
To view or add a comment, sign in
-
We need to further define the terms 'organoids' and 'spheroid' cells. Personally, I disagree with labeling patient-derived cells as 'organoids,' as discussed in this paper. However, this patient-derived cell screening approach could provide a valuable opportunity to discover novel therapeutic options, despite some limitations in immuno-oncology. https://lnkd.in/geVM3pKm
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids - npj Precision Oncology
nature.com
To view or add a comment, sign in
-
CEO and Founder of Genoplex.ai | Comms Committee @ ASGCT | Host of Rx for Biotech Podcast & TEDx Speaker
#celltherapy to treat #autoimmune disease is the next treatment frontier as adoptive cellular therapies move beyond oncology and into other larger, more prevalent diseases with high unmet clinical need. Learn more about this emerging treatment modality in the story below... #advancedtherapies #cartcelltherapy
What is the potential for CAR-T cell therapies to treat autoimmune diseases? BioPharma Dive reviews how these therapies work, how they are different, and which companies are involved in their development, such as ARM members, Bristol Myers Squibb, Kyverna Therapeutics, ImmPACT Bio, Cabaletta Bio, CRISPR Therapeutics, and Autolus Therapeutics. Read the full story: https://lnkd.in/gcpEbyPF
CAR-T for lupus: the ‘tip of the iceberg' for cell therapy in autoimmune disease
biopharmadive.com
To view or add a comment, sign in
-
Significant Advancement in DMD Treatment by Sarepta Therapeutics! While Pfizer's Phase 3 CIFFREO trial for DMD therapy faced setbacks, last Thursday marked a positive shift with Sarepta's ELEVIDYS label receiving FDA approval, expanding treatment options significantly. Previously, only DMD boys between aged 4 and 5 were FDA approved to receive the therapy, and now, all young DMD boys and men aged 4 and above will have access per the FDA expansion. In addition, previously, there were strict ambulatory restrictions whereby if the child required assistance with ambulation, they were excluded from having access, whereby, now, this milestone FDA expansion includes full approval for non-wheelchair-dependent patients and accelerated approval for those who are wheelchair-dependent. Despite initial challenges, secondary clinical trial results demonstrating improved motor functions supported this decision, bringing renewed hope to families affected by this devastating disease. We anticipate many DMD boys who were denied access over the past year, may now meet guidelines for access to this potentially life-changing treatment option per the FDA expansion. Symphony Benefit Solutions is staying on top of developing stories like this in the gene and cell therapy arena. We are excited for the 7/1 launch of our fully integrated program, which will tackle high-cost gene and cell therapy treatments while remaining at the forefront of this rapidly changing environment. Reach out to us to learn more about how Symphony Benefits Solution can help at [email protected] This development highlights the continued progress and breakthroughs in the fight against DMD. #DMD #GeneTherapy #SareptaTherapeutics #FDAApproval #MedicalBreakthrough #SymphonyBenefitSolutions
To view or add a comment, sign in
-
-
Cartesian Therapeutics celebrates a Phase II win with their mRNA CAR-T therapy for myasthenia gravis. Descartes-08 showed a 71% improvement in patients, surpassing the 25% in the placebo group. Notably, this therapy does not require lymphodepleting chemotherapy, allowing for outpatient administration. Insight - Cartesian secured $130M in financing, fueling further development of their innovative mRNA platform and expanding into other autoimmune diseases like systemic lupus erythematosus. Key questions - How will Cartesian's mRNA CAR-T therapy reshape treatment for autoimmune diseases? What implications does this have for future cell therapies? #Biotech #CAR_T #AutoimmuneDisease #HealthcareInnovation #CartesianTherapeutics
Cartesian Gets Phase II Win in Myasthenia Gravis, Looks to Raise $130M in Financing | BioSpace
biospace.com
To view or add a comment, sign in
-
The Evolving Treatment Landscape of Multiple Myeloma: GPRC5D-Targeted CAR T-Cell Therapy: Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma. #finance #pharmacy #lifesciences
The Evolving Treatment Landscape of Multiple Myeloma: GPRC5D-Targeted CAR T-Cell Therapy
pharmacytimes.com
To view or add a comment, sign in